Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results

Rhea-AI Summary

Alvotech (NASDAQ: ALVO) will report its fourth quarter and full year 2025 financial and operating results on Wednesday, March 18, 2026 after U.S. markets close.

The company will host a conference call with live Q&A on Thursday, March 19, 2026 at 08:00 EST (12:00 GMT, 13:00 CET). Slides and materials will be posted on the investor website before the call, and registration is required to access the webcast and Q&A.

Key Figures

Earnings release date: March 18, 2026 Conference call date: March 19, 2026 Conference call time EST: 08:00 EST +3 more

6 metrics

Earnings release date March 18, 2026 Q4 and full year 2025 results to be released after U.S. market close

Conference call date March 19, 2026 Earnings conference call with live Q&A

Conference call time EST 08:00 EST Scheduled start time for earnings call

Conference call time GMT 12:00 GMT Corresponding time for UK listeners

Conference call time CET 13:00 CET Corresponding time for Central Europe

Results period Full year 2025 Annual financial and operating results to be discussed

Market Reality Check

Price: $3.80 Vol: Volume 934,370 is 1.5x th...

normal vol

$3.80 Last Close

Volume Volume 934,370 is 1.5x the 20-day average of 621,421, showing elevated trading ahead of the earnings release date. normal

Technical Shares at $3.80 trade below the 200-day MA of $7.30, about 67.93% under the 52-week high and only 4.11% above the $3.65 52-week low.

Peers on Argus

ALVO fell 4.04% while peers were mixed: SUPN and ANIP gained 0.53% and 1.72%, wh...

ALVO fell 4.04% while peers were mixed: SUPN and ANIP gained 0.53% and 1.72%, whereas BHC, HCM and INDV declined between 1.13% and 2.5%, pointing to stock-specific pressure rather than a unified sector move.

Historical Context

5 past events · Latest: Feb 26 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 26	Intra-group share transfer	Neutral	-4.1%	Disclosure of internal share transfer within Aztiq group at USD 4.74 per share.
Feb 11	Share capital increase	Neutral	-6.7%	Issued 12,500,000 new shares to subsidiary to support prior obligations.
Feb 05	Positive PK study results	Positive	-2.0%	Pivotal AVT80 PK study met all primary similarity endpoints versus Entyvio.
Feb 02	Commercialization deals	Positive	-0.9%	Sandoz agreements for multiple biosimilars in Canada and Australia/New Zealand.
Jan 29	Global settlement deal	Positive	+2.5%	Global settlement enabling staged market entry for Eylea biosimilar.

Pattern Detected

Recent positive and strategic announcements have often seen muted or negative next-day moves, with only one clear positive news item aligning with a price gain.

Recent Company History

Over the last few months, Alvotech reported several material developments, including a global settlement for its Eylea biosimilar, new supply and commercialization agreements, and positive top-line results from a pivotal PK study for AVT80. It also executed a share capital increase via its subsidiary and disclosed intra‑group share transfers. Despite multiple seemingly constructive operational updates, next‑day price reactions were frequently negative. Today’s scheduling of the Q4 and full-year 2025 earnings call follows this stretch of mixed market responses to news.

Market Pulse Summary

This announcement sets the timeline for Alvotech’s fourth quarter and full year 2025 results, with f...

Analysis

This announcement sets the timeline for Alvotech’s fourth quarter and full year 2025 results, with figures to be released on March 18, 2026 and discussed on a conference call the following day. In light of recent clinical, commercial, and regulatory milestones, the upcoming report may help contextualize how these developments translate into revenue and earnings. Investors may focus on any updates relative to previously communicated guidance and pipeline progress.

Key Terms

biosimilar medicines

1 terms

biosimilar medicines medical

"a global biotechnology company specializing in the development and manufacture of biosimilar medicines"

Biosimilar medicines are follow‑on versions of complex biological drugs made from living cells that are highly similar to an original approved biologic but not exact copies, like a near‑identical twin rather than a factory‑made duplicate. They matter to investors because they increase competition and typically lower prices for high‑cost therapies, which can reduce revenue for original drugmakers while creating new market opportunities for companies that develop and sell biosimilars.

AI-generated analysis. Not financial advice.

REYKJAVIK, Iceland, March 04, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it will release its fourth quarter and full year 2025 financial and operating results on Wednesday, March 18, 2026, after the U.S. markets close.

The Company will also host a conference call with a live Q&A on Thursday, March 19, 2026 at 08:00 EST (12:00 GMT, 13:00 CET).

• To listen to the webcast, register here: Q4 and Full Year 2025 webcast registration
• To participate in the Q&A, register here: Q4 and Full Year 2025 conference call registration

Slides and other material will be made available on https://investors.alvotech.com/news-events/events before the call.

For further information, contact:

Media
Benedikt Stefansson
Sarah MacLeod
alvotech.media@alvotech.com

Investors
Dr. Balaji V Prasad (US)
Patrik Ling (SE)
Benedikt Stefansson (IS)
alvotech.ir@alvotech.com

About Alvotech
Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira^® (adalimumab), Stelara^® (ustekinumab), Simponi^® (golimumab), Eylea^® (aflibercept) and Prolia^®/Xgeva^® (denosumab). The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.

For more information, please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram and YouTube.

FAQ

When will Alvotech (ALVO) release Q4 and full year 2025 results?

Alvotech will release Q4 and full year 2025 results on March 18, 2026 after U.S. markets close. According to Alvotech, the release will be followed by a conference call and webcast to discuss financial and operating outcomes for 2025.

What time is the Alvotech (ALVO) conference call and Q&A for Q4 2025?

The conference call with live Q&A is scheduled for March 19, 2026 at 08:00 EST (12:00 GMT, 13:00 CET). According to Alvotech, the call will include management remarks and an opportunity for investors and analysts to ask questions.

How can investors join the Alvotech (ALVO) webcast for Q4 and full year 2025?

Investors must register to access the live webcast via the company's registration link provided for the Q4 and full year 2025 event. According to Alvotech, registration details and access instructions are available on the investor events page.

Where will Alvotech (ALVO) publish slides and materials for the Q4 2025 call?

Slides and supporting materials will be posted on Alvotech's investor events page before the conference call. According to Alvotech, attendees can download presentation slides and other materials from the events section on the investor website.

Who should investors contact for Alvotech (ALVO) investor inquiries about the Q4 2025 results?

Investor inquiries can be directed to the named investor contacts and the investor relations email provided by the company. According to Alvotech, specific US and SE contacts and an investor relations email are available for questions before and after the release.

Will Alvotech (ALVO) offer a live Q&A during the March 19, 2026 call?

Yes, Alvotech will host a live Q&A during the March 19, 2026 conference call immediately following the presentation. According to Alvotech, registered participants can submit questions live during the call for management to address.